PD-1 and CTLA-4 blockade revolutionized the treatment of melanoma and NSCLC, improving survival and offering durable responses (12–14) by reactivating the immune system’s ability to recognize and attack tumor cells (71). Here, CTLA4 is linked to neoplasm.